Update on the management of cirrhosis – focus on cost-effective preventative strategies

References

• HeidelbaughJJBruderlyMCirrhosis and chronic liver failure: part I. Diagnosis and evaluationAm Fam Physician200674575676216970019
   PubMed Web of Science ®Google Scholar
• Garcia-TsaoGLimJKManagement and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C ProgramAm J Gastroenterol200910471802182919455106
   PubMed Web of Science ®Google Scholar
• SchuppanDAfdhalNHLiver cirrhosisLancet2008371961583885118328931
   PubMed Web of Science ®Google Scholar
• CardenasAGinesPManagement of complications of cirrhosis in patients awaiting liver transplantationJ Hepatol200542Suppl 1S124S13315777567
   PubMed Web of Science ®Google Scholar
• LimYSKimWRThe global impact of hepatic fibrosis and end-stage liver diseaseClin Liver Dis2008124733746vii18984463
   PubMed Web of Science ®Google Scholar
• WasleyAGrytdalSGallagherKCenters for Disease Control and PreventionSurveillance for acute viral hepatitis – United States, 2006MMWR Surveill Summ200857212418354374
   PubMedGoogle Scholar
• LavanchyDThe global burden of hepatitis CLiver Int200929Suppl 1748119207969
   PubMed Web of Science ®Google Scholar
• PyensonBFitchKIwasakiKConsequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver DiseaseNew York, NYMilliman, Inc2009 Available from: http://publications.milliman.com/research/health-rr/pdfs/consequences-hepatitis-c-virus-RR05-18-09.pdfAccessed January 18, 2011.
   Google Scholar
• LecuyerALevyCGaudelusJHospitalization of newborns and young infants for chickenpox in FranceEur J Pediatr2010169101293129720461528
   PubMed Web of Science ®Google Scholar
• VrolijkJMde KnegtRJVeldtBJOrlentHSchalmSWThe treatment of hepatitis C: history, presence and futureNeth J Med2004623768215209471
   PubMed Web of Science ®Google Scholar
• DienstagJLMcHutchisonJGAmerican Gastroenterological Association technical review on the management of hepatitis CGastroenterology2006130123126416401486
   PubMed Web of Science ®Google Scholar
• ShepherdJWaughNHewitsonPCombination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic reviewHealth Technol Assess200043316711134916
   PubMedGoogle Scholar
• ShiffmanMLEstebanRTriple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Liver Int201232Suppl 1546022212573
   PubMed Web of Science ®Google Scholar
• McQueenCFDA approves Vertex’s new drug Incivek for treatment of hepatitis C [webpage on the Internet]Princeton, NJThe AIDS Beacon5232011 Available from: http://www.aidsbeacon.com/news/2011/05/23/fda-approves-vertexs-new-drug-incivek-telaprevir-for-treatment-of-hepatitis-c/Accessed January 21, 2013.
   Google Scholar
• BrownREDe CockEColinXAntonanzasFIloejeUHHepatitis B management costs in France, Italy, Spain, and the United KingdomJ Clin Gastroenterol20043810 Suppl 3S169S17415602166
   PubMed Web of Science ®Google Scholar
• DenizBBroganAJMillerJDTalbirdSEThompsonJRProjections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment [abstract]Hepatology201154S1802A803A
   Google Scholar
• CammaCPettaSEneaMCost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis CHepatology201256385086022454336
   PubMed Web of Science ®Google Scholar
• ChhatwalJFerranteSADasbachEJCost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin [abstract]Hepatology201154Suppl 1801A802A21618565
   PubMed Web of Science ®Google Scholar
• FerranteSAChhatwalJElbashaECost-effectiveness of boceprevir based regimens in previously untreated adult subjects with chronic hepatitis C genotype 1 [abstract]Hepatology201154Suppl 1795A796A
   Google Scholar
• GrewalPMartinPCare of the cirrhotic patientClin Liver Dis200913233134019442922
   PubMed Web of Science ®Google Scholar
• ArguedasMRHeudebertGREloubeidiMAAbramsGAFallonMBCost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varicesAm J Gastroenterol20029792441245212358270
   PubMed Web of Science ®Google Scholar
• Garcia-TsaoGSanyalAJGraceNDCareyWPrevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisHepatology200746392293817879356
   PubMed Web of Science ®Google Scholar
• TeranJCImperialeTFMullenKDTavillASMcCulloughAJPrimary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysisGastroenterology199711224734829024301
   PubMed Web of Science ®Google Scholar
• SaabSDeRosaVNietoJDurazoFHanSRothBCosts and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic modelAm J Gastroenterol200398476377012738453
   PubMed Web of Science ®Google Scholar
• D’AmicoGPietrosiGTarantinoIPagliaroLEmergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patientsCochrane Database Syst Rev20021CD00223311869632
   PubMedGoogle Scholar
• O’DonnellTFJrGembarowiczRMCallowADPaukerSGKellyJJDeterlingRAThe economic impact of acute variceal bleeding: cost-effectiveness implications for medical and surgical therapySurgery19808856937016776645
   PubMed Web of Science ®Google Scholar
• RubensteinJHEisenGMInadomiJMA cost–utility analysis of secondary prophylaxis for variceal hemorrhageAm J Gastroenterol20049971274128815233665
   PubMed Web of Science ®Google Scholar
• RussoMWZacksSLSandlerRSBrownRSCost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleedingHepatology200031235836310655258
   PubMed Web of Science ®Google Scholar
• RibeiroTCChebliJMKondoMGaburriPDChebliLAFeldnerACSpontaneous bacterial peritonitis: how to deal with this life-threatening cirrhosis complication?Ther Clin Risk Manag20084591992519209274
   PubMedGoogle Scholar
• DasAA cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosisAm J Gastroenterol19989310189519009772051
   PubMed Web of Science ®Google Scholar
• SabatMKolleLSorianoGParenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleedingAm J Gastroenterol19989312245724629860409
   PubMed Web of Science ®Google Scholar
• LoombaRWesleyRBainACsakoGPucinoFRole of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysisClin Gastroenterol Hepatol20097448749319250986
   PubMed Web of Science ®Google Scholar
• FernandezJRuiz del ArbolLGomezCNorfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhageGastroenterology200613141049105617030175
   PubMed Web of Science ®Google Scholar
• SorianoGGuarnerCTomasANorfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhageGastroenterology19921034126712721397884
   PubMed Web of Science ®Google Scholar
• DupeyronCMangeneyNSedratiLCampilloBFouetPLeluanGRapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitisAntimicrob Agents Chemother19943823403448192461
   PubMed Web of Science ®Google Scholar
• UmgelterAReindlWMiedanerMSchmidRMHuberWFailure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitisInfection20093712819169633
   PubMed Web of Science ®Google Scholar
• YakarTGucluMSerinEAliskanHHusamettinEA recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitisDig Dis Sci20105541149115419424797
   PubMed Web of Science ®Google Scholar
• NavasaMFolloALlovetJMRandomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitisGastroenterology19961114101110178831596
   PubMed Web of Science ®Google Scholar
• RicartESorianoGNovellaMTAmoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patientsJ Hepatol200032459660210782908
   PubMed Web of Science ®Google Scholar
• TuncerITopcuNDurmusATurkdoganMKOral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitisHepatogastroenterology200350531426143014571754
   PubMedGoogle Scholar
• SortPNavasaMArroyoVEffect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitisN Engl J Med1999341640340910432325
   PubMed Web of Science ®Google Scholar
• PoordadFFThe burden of hepatic encephalopathyAliment Pharmacol Ther200725Suppl 13917295846
   PubMed Web of Science ®Google Scholar
• GerberTSchomerusHHepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and managementDrugs20006061353137011152016
   PubMed Web of Science ®Google Scholar
• HartmannIJGroenewegMQueroJCThe prognostic significance of subclinical hepatic encephalopathyAm J Gastroenterol20009582029203410950053
   PubMed Web of Science ®Google Scholar
• Als-NielsenBGluudLLGluudCNon-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trialsBMJ20043287447104615054035
   PubMed Web of Science ®Google Scholar
• PaikYHLeeKSHanKHComparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized studyYonsei Med J200546339940715988813
   PubMed Web of Science ®Google Scholar
• PooJLGongoraJSanchez-AvilaFEfficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled studyAnn Hepatol20065428128817151582
   PubMedGoogle Scholar
• SharmaPAgrawalASharmaBCSarinSKProphylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactuloseJ Gastroenterol Hepatol2011266996100321129028
   PubMed Web of Science ®Google Scholar
• SharmaBCSharmaPAgrawalASarinSKSecondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placeboGastroenterology2009137388589119501587
   PubMed Web of Science ®Google Scholar
• LeevyCBPhillipsJAHospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathyDig Dis Sci200752373774117245628
   PubMed Web of Science ®Google Scholar
• Abou-AssiSVlahcevicZRHepatic encephalopathy. Metabolic consequence of cirrhosis often is reversiblePostgrad Med20011092525411272694
   PubMed Web of Science ®Google Scholar
• AtterburyCEMaddreyWCConnHONeomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trialAm J Dig Dis1978235398406354373
   PubMedGoogle Scholar
• BlancPDauresJPLiautardJLactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trialGastroenterol Clin Biol1994181210631068 French7750678
   PubMedGoogle Scholar
• ConnHOLeevyCMVlahcevicZRComparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trialGastroenterology1977724 Pt 157358314049
   PubMed Web of Science ®Google Scholar
• DawsonAMMcLarenJSherlockSNeomycin in the treatment of hepatic comaLancet195727370081262126813492624
   PubMed Web of Science ®Google Scholar
• RothenbergMEKeeffeEBAntibiotics in the management of hepatic encephalopathy: an evidence-based reviewRev Gastroenterol Disord20055Suppl 3263517713457
   PubMedGoogle Scholar
• StraussETramoteRSilvaEPDouble-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathyHepatogastroenterology19923965425451483668
   PubMedGoogle Scholar
• SidhuSSGoyalOMishraBPSoodAChhinaRSSoniRKRifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)Am J Gastroenterol2011106230731621157444
   PubMed Web of Science ®Google Scholar
• BucciLPalmieriGCDouble-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathyCurr Med Res Opin19931321091188325041
   PubMed Web of Science ®Google Scholar
• FestiDMazzellaGOrsiniMRifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safetyCurr Ther Res1993545598609
   Web of Science ®Google Scholar
• GiacomoFFrancescoAMicheleNOronzoSAntonellaFRifaximin in the treatment of hepatic encephalopathyEur J Clin Res199345766
   Google Scholar
• LoguercioCFedericoADe GirolamoVFerrieriADel Vecchio BlancoCCyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical studyMinerva Gastroenterol Dietol2003491536216481971
   PubMedGoogle Scholar
• MasARodesJSunyerLComparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trialJ Hepatol2003381515812480560
   PubMed Web of Science ®Google Scholar
• MassaPVallerinoEDoderoMTreatment of hepatic encephalopathy with rifaximin: double-blind, double dummy study versus lactuloseEur J Clin Res19934718
   Google Scholar
• HuangEEsrailianESpiegelBMThe cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy – a decision analysisAliment Pharmacol Ther20072681147116117894657
   PubMed Web of Science ®Google Scholar
• BassNMMullenKDSanyalARifaximin treatment in hepatic encephalopathyN Engl J Med2010362121071108120335583
   PubMed Web of Science ®Google Scholar
• LeevyCBEconomic impact of treatment options for hepatic encephalopathySemin Liver Dis200727Suppl 22631
   Web of Science ®Google Scholar
• NeffGWKemmerNZachariasVCAnalysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathyTransplant Proc200638103552355517175328
   PubMed Web of Science ®Google Scholar
• NeffGWKemmerNParkinsonEOutcomes in length of hospital stay in cirrhotics admitted for overt hepatic encephalopathy [abstract]Am Coll Gastroeneterol2012107SupplS601
   Google Scholar
• NeffGWKemmerNParkinsonEReadmission rates and maintenance overt hepatic encephalopathy [abstract]Am Coll Gastroeneterol2012107Suppl 1S184S185
   Google Scholar
• Healthcare Cost and Utilization ProjectAgency for Healthcare Research and Quality [homepage on the Internet]. http://hcupnet.ahrq.govAccessed June 20, 2012.
   Google Scholar